Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics' stock price has experienced significant volatility in the past six months. In Q1 2026, the company reported revenues of $731 million and adjusted EPS of $3.16, exceeding expectations, but Elevidys sales were down due to label restrictions, leading to a share price drop. The CEO's retirement announcement raised leadership uncertainty. Positive early siRNA data lifted shares in March 2026. Sarepta submitted sNDAs to the FDA for AMONDYS 45 and VYONDYS 53. While shares rebounded approximately 16.5% over the month leading up to April 24, 2026, they carried a steep ~65% loss over the past year.

The provided search results do not contain explicit information regarding demand seasonality for Sarepta Therapeutics, Inc.'s products and services. Demand for rare disease treatments is typically driven by patient diagnosis and access to approved therapies rather than seasonal patterns.

Sarepta Therapeutics, Inc. is a global biotechnology company specializing in precision genetic medicine for rare diseases, primarily Duchenne muscular dystrophy (DMD). The company discovers, develops, and commercializes genetic medicines, including RNA-targeted therapies, gene therapy, and gene editing programs. Its major approved products for Duchenne muscular dystrophy include ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta is also advancing a pipeline that includes gene therapy programs like SRP-9003 for Limb-Girdle Muscular Dystrophy and siRNA programs for conditions such as facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, spinocerebellar ataxia, Huntington's disease, and idiopathic pulmonary fibrosis.

Sarepta Therapeutics maintains a significant global presence with its corporate headquarters in Cambridge, Massachusetts, USA. It has extensive U.S. operations, including a Genetic Therapies Center of Excellence in Columbus, Ohio, and other sites in Andover and Burlington, Massachusetts. Internationally, Sarepta has offices and entities in Dublin, Ireland, Switzerland, Japan, and the United Kingdom.

Sarepta Therapeutics' brand reputation has been significantly impacted by challenges related to Elevidys, including research setbacks, safety concerns, and regulatory scrutiny. The FDA limited the therapy's use to ambulatory patients. Sarepta undertook a cost-cutting program in 2025, laying off staff and halting programs. The company is working to stabilize its business and restore confidence, emphasizing expanded field engagement and a growing body of evidence for Elevidys's disease-modifying impact.

Sarepta Therapeutics' ownership is predominantly institutional investors and hedge funds, holding a substantial majority of the company's shares. Key institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Black Bear Offshore Master Fund LP is a significant individual shareholder. Insiders held 4.41% of the company's ownership as of July 29, 2024.